The startup develops CAR-NK cell therapy that utilizes engineered natural killer cells to target and eliminate blood and solid tumors by expressing a CAR protein specific to cancer cells. This approach enhances the efficacy of cell therapies, providing a viable alternative to CAR-T treatments, which often face limitations in effectiveness and accessibility.
Funding
$21.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR-T cell therapies for blood cancers and solid tumors face limitations in efficacy, accessibility, and safety, including cytokine release syndrome and neurotoxicity. The production of autologous CAR-T cell therapies is also complex and expensive, hindering widespread adoption.
Solution
OncoInsight develops allogeneic CAR-NK cell therapies designed to target and eliminate both blood and solid tumors. By engineering natural killer (NK) cells with chimeric antigen receptors (CARs) specific to cancer cells, the company aims to enhance the precision and effectiveness of cell therapies while reducing the risk of adverse effects associated with CAR-T treatments. Their off-the-shelf CAR-NK cell products leverage the inherent advantages of NK cells, such as their natural ability to recognize and kill tumor cells without prior sensitization, offering a potentially safer and more accessible alternative for cancer patients. The company is also developing CAR HSC-derived NK cells for autoimmune disease treatment.
Target Audience
The primary target audience includes cancer patients, particularly those with blood cancers and solid tumors, as well as patients with B cell-driven autoimmune diseases.
Features
- Allogeneic CAR-NK cell therapies for targeting blood and solid tumors
- Engineered NK cells with CARs for enhanced cancer cell recognition and elimination
- Off-the-shelf products for immediate availability and reduced production complexity
- CAR HSC-derived NK cells for autoimmune disease treatment
- Humanized mice for human-specific studies